BMS Reports the US FDA Acceptance of NDA for Deucravacitinib to Treat Plaque Psoriasis
Shots:
- The US FDA has accepted the NDA & EMA has validated the MAA for deucravacitinib to treat PsO with an anticipated PDUFA date is Sept 10, 2022
- The application is based on the P-III POETYK PSO-1 & 2 trials to evaluate deucravacitinib (qd) vs PBO & Otezla in 666 & 1,020 patients with PsO that showed improvements in skin clearance, symptom burden & QoL, well-tolerated with a low rate of discontinuation due to AEs & no lab abnormalities were observed
- Deucravacitinib is an oral, selective TYK2 inhibitor & is being studied in multiple immune-mediated diseases including PsO, PsA, lupus & IBD. The therapy is being evaluated in 3 other P-III studies in PsO i.e., POETYK PSO-3/4 & POETYK PSO-LTE
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com